An interventional study of Cancer Episode Payment Model (CEM) in Breast Cancer, Colon Cancer and Lung Cancer, sponsored by University of Pennsylvania. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-20.
Sponsored by University of Pennsylvania · Not applicable, Interventional, and Health services research
The HMSA Cancer Episode Payment Model (CEM) is a payment model designed to test the effects of better care coordination on health outcomes and costs of care for Hawaii Medical Services Association (HMSA) members with cancer who receive chemotherapy.
The CEM is designed to improve community health, to improve care coordination, quality, and appropriateness of care, to improve patient experience, and to implement a value-based incentive structure that appropriately rewards oncologists for cost-savings and sustained of improved quality of care.
12,544 studies on the registry are indexed under Breast Neoplasms; 2,892 are open to participants now.
This study's enrollment of 7 is below the median of 72 across 9,303 interventional studies indexed under Breast Neoplasms.
Browse Breast Neoplasms studies →University of Pennsylvania is the lead sponsor of 1,635 studies on the registry; 239 are open to participants now.
Of its 154 completed or terminated interventional studies of FDA-regulated products, 104 (68%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Oncologists in this arm will be paid for each member's episode of care. The episode of care is 6 months in duration. Oncologists will have the opportunity to receive performance-based payments based upon a set of 6 quality metrics.
Other: Cancer Episode Payment Model (CEM)
Oncologists in this arm will not receive the intervention and will continue to be paid through fee-for-service.
Oncologists will be paid for an episode of care with the opportunity to receive a value based payment based on 6 quality metrics.
Composite quality score
Quality metrics included in the oncology model will be compared across the two arms.
Time frame: 1 year
Episode cost
Total spending of oncology patients in the episode will be compared across the two arms.
Time frame: 6 months
Utilization of acute and specialty care
Total utilization of acute and specialty care of oncology patients in the episode will be compared across the two arms
Time frame: 6 months
Quality of care at end of life
Quality measures evaluating use of acute care and palliative care services at the end of life will be compared across the two arms
Time frame: 6 months
Survival
All cause mortality will be compared across the two arms
Time frame: one year
Plan to share: No
No publications or documents are linked to this record.
This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Pennsylvania